India, April 15 -- Stereotaxis Inc. (STXS), a U.S.-based company specializing in surgical robotics for minimally invasive heart and vascular procedures, has signed a definitive agreement to acquire Robocath, a French developer of robotic technologies for interventional cardiology and neurointerventions.
The acquisition combines Stereotaxis' magnetic navigation system with Robocath's mechanical robotic platform, creating a fully integrated solution designed to improve precision and efficiency in endovascular surgery. Robocath's flagship R-One+ system is already in use for coronary interventions in Europe, with fifteen installations worldwide, and its next-generation system recently completed first-in-human procedures in France.
Stereotaxis...